Literature DB >> 17567635

Chronic viral hepatitis and TNF-alpha blockade.

G Raftery, B Griffiths, L Kay, D Kane.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567635     DOI: 10.1093/rheumatology/kem082

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.

Authors:  Akihiro Tamori; Tatsuya Koike; Hitoshi Goto; Shigeyuki Wakitani; Masahiro Tada; Hiroyasu Morikawa; Masaru Enomoto; Masaaki Inaba; Tatsuya Nakatani; Masayuki Hino; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2011-01-19       Impact factor: 7.527

2.  Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-26       Impact factor: 4.030

3.  When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?

Authors:  Tim L Jansen
Journal:  Arthritis Res Ther       Date:  2010-01-21       Impact factor: 5.156

4.  Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.

Authors:  Shunsuke Mori
Journal:  Mod Rheumatol       Date:  2011-04-29       Impact factor: 3.023

5.  Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

Authors:  Caroline Charpin; Sandrine Guis; Philippe Colson; Patrick Borentain; Jean-Pierre Mattéi; Patrice Alcaraz; Nathalie Balandraud; Benoit Thomachot; Jean Roudier; René Gérolami
Journal:  Arthritis Res Ther       Date:  2009-11-26       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.